Evidence map›Paper›PMID 40354608›Full record

ArticleJournal of fish diseases2025

Cytotoxicity and Antiparasitic Effects of Toltrazuril Against Enteromyxum leei in Olive Flounders: In Vitro and In Vivo Analyses.

Young Juhn Lee, Yeong Eun Oh, Eung Jun Lee, Lyu Jin Jun, Joon Bum Jeong

Abstract read
In one paragraph

Article in Journal of fish diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Young Juhn LeeDepartment of Marine Life Sciences, Jeju National University, Jeju, Korea.
Yeong Eun OhDepartment of Marine Life Sciences, Jeju National University, Jeju, Korea.
Eung Jun LeeDepartment of Marine Life Sciences, Jeju National University, Jeju, Korea.
Lyu Jin JunDepartment of Marine Life Sciences, Jeju National University, Jeju, Korea.
Joon Bum JeongDepartment of Marine Life Sciences, Jeju National University, Jeju, Korea.ORCID https://orcid.org/0000-0002-0544-4968

Funding

National Research Foundation of Korea
6 · The paper itself

Abstract

The parasite Enteromyxum leei causes serious emaciation disease in marine fish species. Toltrazuril exhibits antiparasitic effects; however, the simultaneous impacts of toltrazuril on parasites and hosts are unclear. Here, we evaluate the cytotoxicity of three commercial toltrazuril products (A, B and C) and the treatment efficacy against E. leei infections in olive flounder (Paralichthys olivaceus). Product A was confirmed safe in Hirame natural embryo cells, even at a toltrazuril concentration of 50 μg/mL, and was selected for further studies. In vitro assays revealed that toltrazuril effectively killed E. leei spores at concentrations of 5.0, 7.5 and 10.0 μg/mL. In vivo experiments on olive flounders infected with E. leei showed that oral toltrazuril administration at doses of 10 and 20 mg/kg body weight for 5 days effectively damaged spores in the fish intestine, with E. leei death confirmed by propidium iodide staining. Administering toltrazuril mixed feed (20 mg/kg) to infected olive flounders in a fish-farm setting also proved effective in killing spores present in the intestine. Furthermore, Hoechst-propidium iodide double staining confirmed that toltrazuril was effective in killing E. leei spores both in vitro and in vivo, indicating its potential as a treatment for emaciation diseases in marine fish.

Indexed as

Fish DiseasesFlatfishesMyxozoaTriazinesAnimalstoltrazurilTriazinesemaciation diseaseEnteromyxum leeimyxosporeanParalichthys olivaceustoltrazuril

Identifiers

PMID40354608
PMCPMC12489424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.